|
1
|
Fitzmorris P, Shoreibah M, Anand BS and
Singal AK: Management of hepatocellular carcinoma. J Cancer Res
Clin Oncol. 141:861–876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takayama T: Surgical treatment for
hepatocellular carcinoma. Jpn J Clin Oncol. 41:447–454. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sengupta B and Siddiqi SA: Hepatocellular
carcinoma: Important biomarkers and their significance in molecular
diagnostics and therapy. Curr Med Chem. 19:3722–3729. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schütte K, Schulz C, Link A and
Malfertheiner P: Current biomarkers for hepatocellular carcinoma:
Surveillance, diagnosis and prediction of prognosis. World J
Hepatol. 7:139–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saito Y, Shimada M, Utsunomiya T, Morine
Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Yamada S and Asanoma M:
Prediction of recurrence of hepatocellular carcinoma after curative
hepatectomy using preoperative Lens culinaris agglutinin-reactive
fraction of alpha-fetoprotein. Hepatol Res. 42:887–894. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wallace DC: Mitochondria and cancer. Nat
Rev Cancer. 12:685–698. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eboli ML, Paradies G, Galeotti T and Papa
S: Pyruvate transport in tumour-cell mitochondria. Biochim Biophys
Acta. 460:183–187. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paradies G, Capuano F, Palombini G,
Galeotti T and Papa S: Transport of pyruvate in mitochondria from
different tumor cells. Cancer Res. 43:5068–5071. 1983.PubMed/NCBI
|
|
11
|
Yang C, Ko B, Hensley CT, Jiang L, Wasti
AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, et al:
Glutamine oxidation maintains the TCA cycle and cell survival
during impaired mitochondrial pyruvate transport. Mol Cell.
56:414–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herzig S, Raemy E, Montessuit S, Veuthey
JL, Zamboni N, Westermann B, Kunji ER and Martinou JC:
Identification and functional expression of the mitochondrial
pyruvate carrier. Science. 337:93–96. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bricker DK, Taylor EB, Schell JC, Orsak T,
Boutron A, Chen YC, Cox JE, Cardon CM, Van Vranken JG, Dephoure N,
et al: A mitochondrial pyruvate carrier required for pyruvate
uptake in yeast, Drosophila, and humans. Science. 337:96–100. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schell JC, Olson KA, Jiang L, Hawkins AJ,
Van Vranken JG, Xie J, Egnatchik RA, Earl EG, DeBerardinis RJ and
Rutter J: A role for the mitochondrial pyruvate carrier as a
repressor of the Warburg effect and colon cancer cell growth. Mol
Cell. 56:400–413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang CJ, Zhou ZG, Holmqvist A, Zhang H, Li
Y, Adell G and Sun XF: Survivin expression quantified by image
pro-plus compared with visual assessment. Appl Immunohistochem Mol
Morphol. 17:530–535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Sousa Abreu R, Penalva LO, Marcotte EM
and Vogel C: Global signatures of protein and mRNA expression
levels. Mol Biosyst. 5:1512–1526. 2009.PubMed/NCBI
|
|
19
|
Vigueira PA, McCommis KS, Schweitzer GG,
Remedi MS, Chambers KT, Fu X, McDonald WG, Cole SL, Colca JR,
Kletzien RF, et al: Mitochondrial pyruvate carrier 2 hypomorphism
in mice leads to defects in glucose-stimulated insulin secretion.
Cell Rep. 7:2042–2053. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gluer AM, Cocco N, Laurence JM, Johnston
ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic
review of actual 10-year survival following resection for
hepatocellular carcinoma. HPB (Oxford). 14:285–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morise Z, Kawabe N, Tomishige H, Nagata H,
Kawase J, Arakawa S, Yoshida R and Isetani M: Recent advances in
the surgical treatment of hepatocellular carcinoma. World J
Gastroenterol. 20:14381–14392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vacanti NM, Divakaruni AS, Green CR,
Parker SJ, Henry RR, Ciaraldi TP, Murphy AN and Metallo CM:
Regulation of substrate utilization by the mitochondrial pyruvate
carrier. Mol Cell. 56:425–435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gray LR, Sultana MR, Rauckhorst AJ,
Oonthonpan L, Tompkins SC, Sharma A, Fu X, Miao R, Pewa AD, Brown
KS, et al: Hepatic mitochondrial pyruvate carrier 1 is required for
efficient regulation of gluconeogenesis and whole-body glucose
homeostasis. Cell Metab. 22:669–681. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma R, Zhang W, Tang K, Zhang H, Zhang Y,
Li D, Li Y, Xu P, Luo S, Cai W, et al: Switch of glycolysis to
gluconeogenesis by dexamethasone for treatment of hepatocarcinoma.
Nat Commun. 4:25082013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Divakaruni AS, Wiley SE, Rogers GW,
Andreyev AY, Petrosyan S, Loviscach M, Wall EA, Yadava N, Heuck AP,
Ferrick DA, et al: Thiazolidinediones are acute, specific
inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad
Sci USA. 110:5422–5427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du J, Cleghorn WM, Contreras L, Lindsay K,
Rountree AM, Chertov AO, Turner SJ, Sahaboglu A, Linton J, Sadilek
M, et al: Inhibition of mitochondrial pyruvate transport by
zaprinast causes massive accumulation of aspartate at the expense
of glutamate in the retina. J Biol Chem. 288:36129–36140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Compan V, Pierredon S, Vanderperre B,
Krznar P, Marchiq I, Zamboni N, Pouyssegur J and Martinou JC:
Monitoring mitochondrial pyruvate carrier activity in real time
using a BRET-based biosensor: Investigation of the warburg effect.
Mol Cell. 59:491–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
